Stock Analysis · Bulls vs Bears

IperionX IPX

🐂 Bulls vs Bears 🐻Report #311 Oct 2026
★ Willem owns this stock · 4.4% of the portfolio
67
high risk▼ −7 vs last
🐂 8vs10 🐻
Bears lead
30%
▲ Chance of the biggest tailwind the forecasts miss
60%
▼ Chance of the biggest headwind the forecasts miss
The verdict

The evidence leans bearish. Output was about 2.4 t in June, against a target of 16.7 t a month by December, and the company sold about US$63k of product in FY26. Its cash is less than one year's outflow before it pays its share of the 1,400 tpa build. The bull case survives on things that are real but not yet commercial: Pentagon funding, a clean balance sheet and the GenX pilot. The September-quarter report (due…

🎙️ Bulls vs Bears podcast — IperionX
Alex and Sam debate every bull and bear argument · 13:12
0:0013:12
⤓ Download

Written by Claude (Anthropic’s AI) from public sources · Willem owns IPX · AI can make mistakes — numbers in brackets point to the sources · Not financial advice

🐂 Bull arguments 8

  1. 1The Pentagon is paying for most of the build-outStrong
  2. 2The US has no titanium sponge plant and 100% import relianceStrong
  3. 3Debt-free balance sheet with a clean audit and effective controlsMedium
  4. 4GenX continuous HAMR could reset the cost curveMedium
  5. 5The fasteners beat their benchmarks, and the Army wants a fleet rollout in 2027Medium
  6. 6Titan is a funded-later option on zircon and heavy rare earthsMedium
  7. 7Insiders bought about US$6M on market and sold nothingWeak
  8. 8The price already assumes a lot of failure, and the shorts are crowdedWeak

🐻 Bear arguments 10

  1. 1Output is about 15% of the year-end run-rate targetHigh
  2. 2Cash is below one year's outflow, before the expansion matchHigh
  3. 3Zero revenue and no binding volume contract after five yearsHigh
  4. 4The Army money buys furnaces, not partsMedium
  5. 5Thin unit economics, with a funded rival scaling firstMedium
  6. 6Short sellers keep adding: ASX shorts rose from 7.8% to 12.5%Medium
  7. 7The founders' pledged shares could become forced sellersMedium
  8. 8Promises keep getting softened or droppedMedium
  9. 9The Titan study relies on rich prices, unpermitted plants and no offtakeMedium
  10. 10The Texas redomiciliation adds cost and US litigation exposureLow

Bull arguments show how well they survive the devil’s advocate (strong / medium / weak); bear arguments show the damage they could do after the counter-argument (high / medium / low).

Bull case

🐂 Bull #1The Pentagon is paying for most of the build-out

  • The point: Department of War money pays for most of the equipment, supplies the feedstock and gives a fast contracting route. That lowers the equity IperionX needs and marks it as a strategic supplier.
  • Evidence:
    • DPA Title III (US$12.7M) and IBAS (US$47.1M) are both fully obligated. US$22.7M has been reimbursed and US$37.1M is still to be reimbursed at 30 June 2026. US$2.4M of DPA money arrived in July [6].
    • The SBIR Phase III IDIQ has a US$99M ceiling, with about US$79.2M still unordered after Task Order 2 [12].
    • A Navy submarine industrial-base award (OSW-SWIB) of up to US$6.6M was announced 2026-07-01 [11].
    • The government transferred 290 t of scrap at no cost (fair value US$2.76M) [1].
  • Why it matters: each reimbursed dollar of capex is a dollar not raised at US$16 per ADS. The IDIQ lets the Army add task orders without a new competition.
  • 😈 Devil's advocate:
    • The IBAS money comes with a US$49.2M company match, so it creates an equity need as well as easing one [1].
    • Title to government-funded equipment vests in the US government [1], and the DPA agreement ends 2027-01-30 [1].
    • The stopgap budget signed 2026-09-02 runs to 2026-12-11. It holds programmes at FY26 levels, bars Department of War funds for "new production of items not funded for production in fiscal 2026 or earlier", and bars production-rate increases [39,40]. That is exactly the step from prototype to serial order that IperionX needs.
  • Verdict: Strong for survival and validation, Weak as a revenue point. Washington lowers the chance of failure but is not yet buying product at scale.

🐂 Bull #2The US has no titanium sponge plant and 100% import reliance

  • The point: the US depends entirely on imported titanium metal while defence demand rises. A domestic, non-Kroll route has a structural customer: the Kroll process is the century-old batch method used to make titanium metal.
  • Evidence:
    • The US made no sponge in 2025. The last plant (Utah, ~500 tpa) closed in 2024, Henderson (12,600 tpa) has been idle since 2020 and Rowley (10,900 tpa) since 2016 [30].
    • Imports were a record ~44,000 t in 2025, worth about US$460M. About 73% came from Japan [30].
    • China made 260,000 t of the world's 370,000 t of sponge in 2025 [30]. The 20-F puts China plus Russia at about 80% of sponge capacity [1].
    • ATI, a US titanium mill-product producer, reported Q2 2026 aerospace and defence sales up 13% and backlog up 18% [51].
  • Why it matters: defence programmes can pay a premium for short lead times and domestic origin, which is IperionX's segment.
  • 😈 Devil's advocate:
    • The supply comes from an ally. Landed sponge was about US$12/kg in 2025 [30], and Chinese grade-0 sponge was about US$7.1–7.4/kg FOB in May 2026 [34].
    • Osaka Titanium is adding 10,000 tpa by FY2027. IperionX's 1,400 tpa target equals about 3% of 2025 US imports.
    • Strategic need does not set a price.
  • Verdict: Strong The gap is documented by USGS. The open question is whether IperionX captures it.

🐂 Bull #3Debt-free balance sheet with a clean audit and effective controls

  • The point: unlike many pre-revenue industrial names, IperionX has no bank debt, no convertibles and no going-concern doubt. The March "typo" was smaller than feared.
  • Evidence:
    • Loans and borrowings are US$4.16M: leases US$3.97M and financed insurance premiums US$0.19M. There are no credit facilities, no EXIM loan and no warrants [1].
    • PwC gave unqualified opinions on the accounts and on internal controls (ICFR), dated 2026-09-29. There is no going-concern emphasis [1].
    • Past material weaknesses (first reported in FY22) were remediated by 30 June 2025 [2].
    • The 2026-03-13 correction moved US$17.7M between two columns of the property, plant and equipment (PP&E) note: right-of-use assets were shown as US$21,445,038 instead of US$3,752,600. The total was unchanged [8,1].
    • Correction of my report #2: plaintiff-firm material cited "~US$330M". That figure is wrong, and I should not have repeated it.
  • Why it matters: with no lender, there is no lender to force a fire sale. The company can slow spending on GenX, Titan and the pace of 1,400 tpa, which the going-concern note lists as levers [1].
  • 😈 Devil's advocate:
    • "No debt" partly reflects that no lender would lend against a plant with no revenue.
    • Pro-forma cash of about US$84M is below FY26 operating plus investing outflow of US$63.5M plus the US$49.2M IBAS match [1,6].
    • A column swap in a half-year note, two weeks before an equity raise window, still cost about a third of the market value in four days [7,22].
  • Verdict: Medium It removes default risk, not funding risk.

🐂 Bull #4GenX continuous HAMR could reset the cost curve

  • The point: a continuous (non-batch) version of the reduction step would cut energy and reagent use per kg. That could make parts cheaper than forged-and-machined parts, not just more domestic.
  • Evidence:
    • Four campaigns processed more than 500 kg in 41 hours (about 12 kg/h). Throughput was 6× batch on a like-for-like basis. Power was more than 75% lower, magnesium more than 45% lower and hydrogen more than 60% lower per kg [13].
    • Oxygen met Grade 5 in 7 of 8 angular samples, Grade 23 in 4 of 8 angular samples, and Grade 23 in all spherical samples [13].
    • The projected cost is about US$55/kg at 200 tpa and about US$29/kg operating cost at 1,400 tpa [1,3].
    • Jefferies (2026-09-02, Buy, US$26) reportedly credits about 90% lower energy, 70–80% lower capex and about 50% lower opex versus incumbents (secondary summary [24]).
  • Why it matters: each US$5/kg of cost or price is worth about US$7M of EBITDA at 1,400 tpa, per Jefferies' published sensitivity [24].
  • 😈 Devil's advocate:
    • This is a pilot result. One sample from an "interrupted furnace run" was excluded [13].
    • The company says GenX is "not required" for the 200 tpa or Virginia expansion plans [13], so it does not fix today's bottleneck.
    • No realised cost per kg has ever been disclosed. The batch plant runs at about 15% of its 200 tpa target.
  • Verdict: Medium It is real technical progress, but zero commercial evidence until a production line runs it (next stage: Q4 2026 [13]).

🐂 Bull #5The fasteners beat their benchmarks, and the Army wants a fleet rollout in 2027

  • The point: near-net-shape fasteners and track pins are repeat-order items. If they are qualified on a vehicle fleet, they reorder for years at component prices (company target US$180–400/kg).
  • Evidence:
    • In Army and independent testing, yield torque was up to about 20% above SAE Grade 8 steel [1].
    • A first low-rate fastener order of about US$300k (about 3 t of titanium) came in 2025. The company's deck targets a "full fleet rollout" in 2027, "subject to prototyping and commercial negotiations" [48].
    • A JLTV (Joint Light Tactical Vehicle) prototype fastener PO was announced 2026-07-01; its value was "not considered material" [11].
    • American Rheinmetall: about US$0.3M for 700 track pins (January 2026) [1].
    • Task Order 2 includes US$1.0M for in-house centerless grinding and thread rolling, and a track-pin and bolt production package [12].
  • Why it matters: this is the most concrete route to recurring revenue in FY27–28.
  • 😈 Devil's advocate:
    • All named orders are prototypes, together well under US$1M.
    • A fleet rollout in 2027 collides with the budget stopgap's ban on new production starts until full-year FY27 appropriations pass [40].
    • Titanium fasteners compete with steel on price per part.
  • Verdict: Medium

🐂 Bull #6Titan is a funded-later option on zircon and heavy rare earths

  • The point: the Tennessee mineral-sands deposit adds titanium feedstock, zircon and a heavy rare-earth concentrate (HREC, containing dysprosium and terbium) that the West cannot easily source.
  • Evidence:
    • Feasibility study (DFS): NPV8 US$813M, IRR 39.4%, Phase 1 capex US$228.1M. Phase 2 output includes 5,287 tpa of HREC with about 48 tpa Dy₂O₃ and 11 tpa Tb₄O₇ [16].
    • Zircon is strengthening: Iluka's Q3 contracts are about US$1,760/t, versus US$1,546/t realised in Q2 [31].
    • Fastmarkets, as quoted 2026-09-10, had dysprosium oxide in Rotterdam at US$1,250–1,675/kg versus US$270–330/kg FOB China (secondary, [35]). REEx reports North American terbium oxide at about US$7,500/kg (2026-10-02, [36]).
    • Jefferies reportedly values Titan at about US$15 per share. It says a final investment decision (FID) adds about US$3 and a financing delay subtracts about US$5 (secondary [24]).
  • Why it matters: a financed Titan could be worth a large part of today's ~US$0.6B market value.
  • 😈 Devil's advocate:
    • The DFS uses rutile at US$1,471/t, against Iluka's realised US$1,256/t [16,31].
    • There is no binding offtake [16]. The separation and rare-earth plants are not yet permitted [1]. The model assumes 100% equity.
    • The ex-China premium depends on Chinese policy, and the suspension of China's export controls expires 2026-11-10 [43].
  • Verdict: Medium Weak.

🐂 Bull #7Insiders bought about US$6M on market and sold nothing

  • The point: the people with the furnace data put personal money in.
  • Evidence:
    • Open-market buys (code P), with no sales, across all 29 Form 3/4 filings since 2026-03-18:
      • Arima, Hannigan, Symonds and Tripeny on 03-27.
      • Arima, Hannigan, Symonds and Martin on 04-28/29.
      • Arima, Hannigan, Symonds, Martin and Tripeny on 07-10 to 07-14, at A$3.58 or about US$24.5–26 per ADS [19].
    • 17.8% of votes opposed the founders' performance rights in March [15].
    • Hannigan holds 26.63M shares (7.8%) [20,1].
  • Why it matters: it is a cheap signal of conviction in the ramp.
  • 😈 Devil's advocate:
    • No insider has bought since 2026-07-14, while the ADS fell from about US$25 to US$15–16 [19].
    • Part of both founders' holdings is pledged to lenders (see Bear #7). On 2026-07-09, Hannigan pledged 2.55M more shares the day after the raise [20].
    • Buying while borrowing against the same stock is weaker evidence than it looks.
  • Verdict: Weak (was Medium). The silence since July and the pledges outweigh the earlier buying.

🐂 Bull #8The price already assumes a lot of failure, and the shorts are crowded

  • The point: at US$16.48 the ADS is down about 55% YTD and near its 52-week low (US$15.05 intraday on 2026-10-08). Any good quarter meets a large short base.
  • Evidence:
    • Market value is about US$597M, and EV about US$510M on pro-forma cash (estimate) [28].
    • The average target is about US$42 (range US$26–55; 6 of 7 analysts Buy) [29].
    • ASX short positions are 45.1M shares, or 12.45% of issued capital (2026-10-05) [21].
    • On 2026-10-09 the ADS rose 7.85% without news [28]. A German commentary site called the slide a "Vertrauenskrise" (crisis of confidence) with no new company news [27].
  • Why it matters: if September-quarter output shows a real step-up, short covering could add to the move.
  • 😈 Devil's advocate:
    • The average target is stale. The two most recent changes were cuts: Roth 75→53 and B. Riley 52→34 [25]. The newest initiation (Jefferies, US$26) is the lowest.
    • EV of about 5× a single-model FY28 revenue estimate (US$103M [28]) is not cheap for a company with no revenue.
    • The shorts have been right every month since March.
  • Verdict: Weak

Bear case

🐻 Bear #1Output is about 15% of the year-end run-rate target

  • The point: a year after "full commissioning", output is a small fraction of the 200 tpa rate promised for December 2026, and it fell after March.
  • Evidence:

    • Monthly output, read from the bar chart in the June-quarter report, so approximate [6]:

      Month Output (t)
      January ~1.3
      February ~2.6
      March 4.2
      April ~0.9
      May ~1.8
      June ~2.4
      July (forecast) ~3.5

    • The June quarter was about 5.1 t, against about 8.1 t in the March quarter.

    • 200 tpa equals 16.7 t a month, about 7× the June rate [6].

    • The bottleneck HSPT sintering furnaces were "scheduled for commissioning in the June quarter" [5]. By 2026-07-30 only the first large furnace was "being installed", and the second was "expected shortly" [6].

    • The furnace fault's cause and duration are undisclosed [6].

    • Nothing on July–September output has been published as of 2026-10-11 (EDGAR filings through 2026-09-29 [19]).

  • Why it matters: unit cost, qualification and the FY28 revenue consensus all depend on volume.
  • 🛡️ Counter-argument:
    • The July forecast bar (~3.5 t) shows recovery.
    • The furnace OEM fixed the fault, and powder supply to downstream production "was not affected" [6].
    • March output was mostly lower-yield spherical powder [5].
  • Severity: High Even a good September quarter needs a 4–5× further rise in three months.

🐻 Bear #2Cash is below one year's outflow, before the expansion match

  • The point: the money does not cover the plan.
  • Evidence:
    • Cash was US$35.2M at 30 June. Pro forma it is about US$84M, after the US$46M net July raise and the US$2.4M DPA receipt [6,9].
    • FY26 operating plus investing outflow was US$63.5M (FY25 US$46.1M, FY24 US$25.1M) [1].
    • Quarterly operating burn was US$7.8M, 8.9M, 16.3M and 11.9M [3,4,5,6].
    • Still to fund: the US$49.2M IBAS match [1], the 1,400 tpa build (estimated at about US$75M [3]), and Titan Phase 1 (US$228.1M) [16].
    • Consensus FY27 FCF is about −US$73M (one model [28]).
    • No at-the-market (ATM) programme, credit line or new F-3 shelf was found. The July raise used shelf 333-273519 [9].
  • The July raise priced below the market, and the ASX shares fell up to 18.8% intraday on the day [23].
  • Why it matters: at US$16.48, raising US$100M means about 6.1M new ADS, roughly 17% dilution (arithmetic).
  • 🛡️ Counter-argument:
    • There is US$37.1M of obligated reimbursement still to come [6].
    • Spending on GenX, Titan and Atlas is discretionary [1].
    • The company says it has "demonstrated continuing access to equity capital markets" (more than US$250M raised [1]).
  • Severity: High

🐻 Bear #3Zero revenue and no binding volume contract after five years

  • The point: there is no recognised revenue, no realised price and no binding volume deal.
  • Evidence:
    • The 20-F reports no revenue in FY26 or any of the four prior years. Customer receipts were US$63k in FY26, down from US$569k in FY25 [1].
    • The June quarter brought in US$8k [6].
    • The company's own pipeline table puts aerospace entry at 2028 and consumer electronics at 2027–28, with sales cycles of 6 to more than 12 months [5].
  • Why it matters: consensus FY28 revenue of about US$103M (+1,207%) has no contract behind it [28].
  • 🛡️ Counter-argument: defence qualification normally precedes volume by a year or more. Task Order 2 builds the finishing capacity needed for volume supply [12].
  • Severity: High

🐻 Bear #4The Army money buys furnaces, not parts

  • The point: headlines about "US$99M Army contract" and "US$25.4M task order" are mostly equipment funding, not product revenue.
  • Evidence:
    • Task Order 2's funded packages:
      • continuous HSPT furnace development US$3.4M;
      • industrial continuous HSPT and dehydrogenation furnaces US$7.1M;
      • fastener machines US$1.0M;
      • the rest is an initial allotment for track pins and bolts [12].
    • The release says funding "do[es] not represent cash received or revenue recognized" [12].
    • The SBIR line shows "P.O. invoiced —, funds received —" at 30 June [6].
    • The 20-F quotes Task Order potential at US$26.7M (1.3 + 25.4), while the release states about US$19.8M. That is a small inconsistency [1,12].
  • Why it matters: investors pricing the IDIQ ceiling as backlog overstate near-term revenue.
  • 🛡️ Counter-argument: the government is paying to remove the exact sintering bottleneck that limits output. That is better than IperionX paying for it.
  • Severity: Medium

🐻 Bear #5Thin unit economics, with a funded rival scaling first

  • The point: at 200 tpa the projected cost is above the price the most cautious bull assumes, and a better-funded scrap-to-powder rival reaches 1,000 tpa first.
  • Evidence:
    • The company's projected steady-state cost is about US$55/kg at 200 tpa [1]. Jefferies models an average selling price of US$50/kg in 2027 (secondary [24]).
    • 6K Additive (ASX: 6KA):
      • Q2 2026 revenue was US$7.1M, backlog US$11.9M [33].
      • It broke ground on 2026-03-30 on a powder expansion from about 200 to 1,000 tpa, with first production due by end-2026 [32].
      • It has a DPA grant of US$23.4M and an approved EXIM loan of US$27.4M [32].
    • Chinese sponge sells at about US$7/kg [34].
  • Why it matters: powder alone risks becoming a commodity. Only qualified parts earn the US$180–400/kg the plan needs.
  • 🛡️ Counter-argument:
    • US$55/kg is a cost at 200 tpa, while US$50/kg is a price assumption in a 1,400 tpa model, so they are not like for like.
    • At 1,400 tpa the projected cost is US$29/kg [3].
    • Parts, not powder, are the business model.
  • Severity: Medium High.

🐻 Bear #6Short sellers keep adding: ASX shorts rose from 7.8% to 12.5%

  • The point: an informed, growing short base is betting on dilution or failure.
  • Evidence:

    • ASIC aggregate short positions [21]:

      Date Short position (% of issued)
      2026-03-10 7.75%
      2026-07-31 9.86%
      2026-09-25 12.67%
      2026-10-02 12.90%
      2026-10-05 12.45% (45.1M shares)

    • Nasdaq short interest is a further ~1.25M ADS (stockanalysis) or 3.44% of float (MarketBeat), at about 3–4 days to cover [28,29].

    • Spruce Point's report (2025-11-12) and its 2025-12-01 update alleged undisclosed entities linked to the CEO (PowerChem Inc., PowerChem Land LLC, GX Technologies LLC) and urged an independent review [18]. No 2026 Spruce Point report was found.

  • Why it matters: a large short base makes every equity raise more expensive and amplifies bad quarters.
  • 🛡️ Counter-argument:
    • The company rebutted Spruce Point [17].
    • No class action has been filed; only plaintiff-firm "investigations" (March 2026) [47].
    • The 20-F reports no material legal proceedings [1].
  • Severity: Medium

🐻 Bear #7The founders' pledged shares could become forced sellers

  • The point: both founders have borrowed against their IperionX shares. A further fall could trigger margin-call selling into a heavily shorted stock.
  • Evidence (ASX Appendix 3Y) [20]:
    • Hannigan's DITM Family Trust has a UBS AG loan facility. On 2026-07-09 he transferred 2,548,571 more shares as security, for 6.44M pledged (about 24% of his 26.6M).
    • Arima's Moshos Family Trust facility was secured on 6.85M shares. After 750,000 were returned on 2026-07-08, 4.85M remain (about 39% of his roughly 12.5M).
    • A further 1.0M return around 2026-09-30 is UNCONFIRMED (aggregators only).
    • Together the pledges are about 11.3M shares, or 3.1% of issued capital (arithmetic).
  • Why it matters: the July top-up suggests loan-to-value pressure after the raise. The stock has since fallen another ~35% in A$ terms.
  • 🛡️ Counter-argument: loan repayments and share returns suggest the founders are cutting leverage, not adding to it. Neither has sold a share on market.
  • Severity: Medium Low. The stake is small against 45M shares short, but the signal for the share price would be bad.

🐻 Bear #8Promises keep getting softened or dropped

  • The point: dated milestones slip, and the words around them weaken.

  • Evidence:

    Promise Then Now
    "Demonstrated steady-state production" (Oct 2025 [3]) "an early-stage ramp rate, not steady-state capacity" (Apr 2026 [5])
    "Positive EBITDA inflection point projected by year-end 2026" (Oct 2025 [3]) Absent from the March and June reports and the 20-F [1,5,6]
    1,400 tpa "commissioning planned for mid-2027" [3] "targeted during 2027" [1]
    Sintering furnaces Due in the June quarter [5] Still being installed on 07-30 [6]
    FY26 year-end cash Guided US$36–40M [5] Came in at US$35.2M [6]
    • Brokers have been cutting: B. Riley cited a higher H2 loss and R&D above forecast (secondary [25,26]).

  • Why it matters: each softened promise raises the discount the market applies to the next one, including the 200 tpa December target.

  • 🛡️ Counter-argument: some milestones were delivered (Titan DFS, SACMI press). The cash miss was a timing slip of US$2.4M [6].

  • Severity: Medium.

🐻 Bear #9The Titan study relies on rich prices, unpermitted plants and no offtake

  • The point: the US$813M NPV is not bankable yet.
  • Evidence:
    • Rutile is priced at US$1,471/t, against Iluka's realised US$1,256/t [16,31].
    • There is no binding offtake [16].
    • The separation and rare-earth plants are unpermitted, and the mining permit is up for renewal on 2028-08-14 [1].
    • The model assumes 100% equity funding, against a company market value of about US$0.6B.
  • Why it matters: a Titan financing delay costs about US$5 per share in Jefferies' framework (secondary [24]).
  • 🛡️ Counter-argument: zircon and ex-China heavy-rare-earth prices are above the deck assumptions [31,35]. Government precedents exist: MP Materials (US$400M preferred plus a US$150M loan) and Trilogy Metals (a Department of War equity stake, 2026-08-28) [49,50].
  • Severity: Medium Low for the business, Medium for the share price.

🐻 Bear #10The Texas redomiciliation adds cost and US litigation exposure

  • The point: a scheme of arrangement would move the parent company to Texas and end foreign-private-issuer status.
  • Evidence:
    • It needs 75% of votes cast plus a majority by number of holders, and court approval [14].
    • No scheme booklet or meeting date has been published, and the 20-F warns of delays [1].
  • Why it matters: cost and distraction during the ramp, and a US securities-litigation venue for any future claims.
  • 🛡️ Counter-argument: it could simplify the share structure (ADS to common stock) and open US index eligibility. That is interpretation.
  • Severity: Low

Tailwinds NOT in the forecasts

Base for sizing:

  • Consensus FY27 (June-2027) revenue is US$7.89M, FY27 FCF −US$73M and FY28 revenue US$103.2M. All rest on about one model [28].

  • EPS is negative and FY28 EPS consensus is not available, so impacts are shown as EBITDA per ADS, using Jefferies' reported 2027 EBITDA of about US$28M at 1,400 tpa and US$50/kg (secondary [24]).

  • ADS count is about 36.2M (362.2M shares ÷ 10).

  • GenX cuts unit cost at the 1,400 tpa plant — 30% chance within 36 months

    • Impact on revenue: none directly (cost effect).
    • Impact on EPS: +US$0.19 EBITDA per ADS in FY28, about +25% versus the Jefferies-based ~US$0.77 per ADS.
    • How we got the number (estimate): a US$5/kg cost cut (about 9% of the US$55/kg projection) × 1,400 t = US$7.0M ÷ 36.2M ADS ≈ +US$0.19.
    • Expected value: 30% × US$0.19 ≈ +US$0.06 per ADS.
    • What it is: GenX power use (−75%), magnesium (−45%) and hydrogen (−60%) per kg carried into a production line [13].
    • Why it's not priced in: the company says GenX is "not required" for its plans, and no consensus or company cost figure includes it [13].
    • Trigger to watch: the Q4 2026 GenX production-line integration result, and any updated cost per kg.
    • Why this probability: the pilot data are strong, but scaling a pilot reactor into a production line has failed before at this company (batch ramp). The plant it would join does not exist yet.

  • Government financing package for the 1,400 tpa build and/or Titan — 24% chance within 24 months

    • Impact on revenue: none in FY27–28. Titan revenue starts in 2028 or later.
    • Impact on EPS: +US$0.11 EBITDA per ADS in FY28 (+17%) from avoided dilution.
    • How we got the number (estimate): this avoids a ~US$100M raise at ~US$16.5 (6.1M ADS). US$28M ÷ 36.2M ADS = US$0.77, against US$28M ÷ 42.3M = US$0.66, a difference of +US$0.11.
    • Expected value: 24% × US$0.11 ≈ +US$0.03 per ADS.
    • What it is: an OSC, EXIM or DOE loan, or a Department of War equity stake. Precedents: MP Materials (US$400M preferred plus a US$150M loan) and Trilogy Metals (equity, 2026-08-28) [49,50].
    • Why it's not priced in: the DFS assumes 100% equity [16], and consensus FCF assumes self-funding [28].
    • Trigger to watch: a letter of interest from EXIM or OSC, or a Department of War critical-minerals award naming titanium. OSC's current window (closes 2026-11-01) is for fund managers, so IperionX could only be a portfolio company [42].
    • Why this probability: precedents and policy support exist. Against that, titanium is not named in the January 2026 Section 232 proclamation [37], and Titan has no offtake to lend against.

  • Serial (non-prototype) Army or Rheinmetall parts order — 30% chance by June 2028

    • Impact on revenue: +US$10M in FY28, about +10% versus the US$103.2M consensus.
    • Impact on EPS: +US$0.10 EBITDA per ADS in FY28 (+13%).
    • How we got the number (estimate): US$10M × 35% incremental margin = US$3.5M ÷ 36.2M ADS ≈ +US$0.10.
    • Expected value: 30% × US$0.10 ≈ +US$0.03 per ADS.
    • What it is: a funded production task order for JLTV fasteners or track pins, or Rheinmetall serial pricing.
    • Why it's not priced in: every disclosed order is a prototype. The composition of the FY28 consensus is unknown, so some of this may already be in it. That is a caveat.
    • Trigger to watch: Task Order 3 with a parts (not equipment) scope, and full-year FY27 appropriations ending the new-start ban [40].
    • Why this probability: test data are good and the company targets a 2027 fleet rollout [48]. The budget stopgap and the qualification cycle argue for later.

  • Section 232 price floor or titanium-specific trade protection — 9% chance within 24 months

    • Impact on revenue: +US$7M in FY28 (+7% versus consensus), from US$5/kg higher realised pricing × 1,400 t.
    • Impact on EPS: +US$0.19 EBITDA per ADS (+25%).
    • How we got the number (estimate): Jefferies' sensitivity of +US$5/kg ≈ +US$7M EBITDA, ÷ 36.2M ADS.
    • Expected value: 9% × US$0.19 ≈ +US$0.02 per ADS.
    • What it is: minimum import prices under the processed-critical-minerals Section 232 action [37,38].
    • Why it's not priced in: the action chose negotiation, and titanium is not named in it. No post-July outcome was found.
    • Trigger to watch: a Commerce or USTR price-floor announcement covering titanium.
    • Why this probability: the tool is live, but the main supplier (Japan) is an ally and the 2020 sponge case ended without duties.

  • Ex-China offtake or prepayment for Titan's heavy rare-earth concentrate — 14% chance within 36 months

    • Impact on revenue and EPS: not quantifiable for FY27–28, because Titan produces nothing before 2028.
    • Value effect: Jefferies' framework puts FID at about +US$3 per share (secondary [24]).
    • What it is: a binding HREC offtake with a Western separator, along the lines of Iluka's minimum-price magnet offtakes [31].
    • Why it's not priced in: no offtake exists [16].
    • Trigger to watch: an MOU with Energy Fuels, MP Materials, Iluka or a magnet maker.
    • Why this probability: the premium is real (dysprosium about 5× China in Europe [35]), but buyers prefer near-term feed, and Titan lacks permits and financing.

Headwinds NOT in the forecasts

  • 1,400 tpa slips two or more quarters, cutting FY28 volume — 60% chance

    • Impact on revenue: −US$50M in FY28, about −48% versus the US$103.2M consensus.
    • Impact on EPS: −US$0.55 EBITDA per ADS in FY28.
    • How we got the number (estimate): half of FY28 consensus volume lost × an assumed ~40% EBITDA margin (Jefferies' implied: US$28M on ~US$70M) = −US$20M ÷ 36.2M ≈ −US$0.55.
    • Expected value: 60% × −US$0.55 ≈ −US$0.33 per ADS.
    • What it is: the 1,400 tpa plant commissions in H1 calendar 2028 instead of "during 2027".
    • Why it's not priced in: FY28 consensus revenue of +1,207% assumes the plant runs through FY28 [28].
    • Trigger to watch: September- and December-quarter output, a 1,400 tpa capex figure (still "studies underway"), and long-lead equipment orders.
    • Why this probability: the 200 tpa plant is about 15% of target 18 months after commissioning, the 1,400 tpa date has already moved once, and its funding is not secured.

  • Realised price well below the US$50/kg the bull models use — 38% chance

    • Impact on revenue: −US$14M in FY28 (−14%).
    • Impact on EPS: −US$0.39 EBITDA per ADS in FY28.
    • How we got the number (estimate): a US$10/kg lower price × 1,400 t = −US$14M, all falling to EBITDA, ÷ 36.2M ADS.
    • Expected value: 38% × −US$0.39 ≈ −US$0.15 per ADS.
    • What it is: powder sold into a market with Chinese sponge at about US$7/kg [34] and 6K Additive's 1,000 tpa arriving first [32].
    • Why it's not priced in: no realised price exists, and the bull models assume US$50/kg [24].
    • Trigger to watch: the first disclosed contract price, and 6K Additive's pricing commentary.
    • Why this probability: parts pricing could offset this, but a mostly-powder FY28 mix is likely before parts qualify.

  • Equity raise of ≥15% of the share count below US$20/ADS within 12 months — 65% chance

    • Impact on revenue: none.
    • Impact on EPS: −US$0.11 EBITDA per ADS in FY28 (−15%).
    • How we got the number (estimate): 6.1M new ADS: US$28M ÷ 42.3M = US$0.66, against US$0.77.
    • Expected value: 65% × −US$0.11 ≈ −US$0.07 per ADS.
    • What it is: a placement or offering to fund the IBAS match or 1,400 tpa.
    • Why it's not priced in: consensus targets assume a flat share count [28].
    • Trigger to watch: quarter-end cash below about US$55M, a new F-3, or ATM language.
    • Why this probability: cash covers roughly 12–19 months, before the match. The company has raised every 6–12 months (July 2025, July 2026 [1]). A government substitute within 12 months is unlikely.

  • Budget stopgap or full-year CR delays serial orders and new task orders — 45% chance

    • Impact on revenue: −US$2M in FY27 (−25% versus US$7.89M).
    • Impact on EPS: −US$0.03 FCF per ADS in FY27 (about −1.5% versus −US$2.02).
    • How we got the number (estimate): a one-quarter delay on about a quarter of FY27 revenue × an assumed ~50% contribution margin ≈ −US$1M ÷ 36.2M ADS.
    • Expected value: 45% × −US$0.03 ≈ −US$0.01 per ADS.
    • What it is: the 2026-12-11 stopgap gets extended. Its ban on new production starts and on production-rate increases blocks a fleet rollout [39,40].
    • Why it's not priced in: the company has not addressed it. Consensus FY27 assumes a revenue start.
    • Trigger to watch: a full-year FY27 defence appropriations vote before 2026-12-11.
    • Why this probability: long CRs are common, but defence is often funded first.

  • China extends or loosens its rare-earth export controls, shrinking the ex-China premium — 35% chance within 12 months

    • Impact on revenue and EPS: not quantifiable for FY27–28 (Titan has no production).
    • Value effect: a loss of part of the Jefferies Titan value (about US$15/share), for example −20% ≈ −US$3 per share (estimate).
    • What it is: the suspension of the October-2025 controls expires 2026-11-10 [43]. A two-month extension to 2027-01-10 is single-source [44]. The April-2025 heavy rare-earth licensing stays [43].
    • Why it's not priced in: Titan bull cases use current ex-China premiums [24,35].
    • Trigger to watch: an MOFCOM notice before 2026-11-10.
    • Why this probability: both sides tend to extend truces, but loosening the April 2025 controls is less likely.

  • Class action filed, or a second short report published — 22% chance within 12 months

    • Impact on revenue and EPS: not quantifiable. Legal cost is small; the damage would come through the cost of equity.
    • What it is: a lawsuit over the March correction, or a Spruce Point follow-up.
    • Why it's not priced in: only investigations exist [47].
    • Trigger to watch: a court filing, or a short publication around the redomiciliation vote.
    • Why this probability: the corrected figure was small (US$17.7M, balance-sheet total unchanged), which weakens a damages theory.

Investment Risk Score: 67/100 (high)

# Factor Weight Measured value Score Why
1 Liquidity & funding runway 15% Runway ~12–19 months: pro-forma cash ~US$84M; operating plus investing burn US$13–19M/qtr; US$49.2M IBAS match unfunded; no credit lines 76 Inside the 12–36-month band but at its short end once the match is spent. No going-concern doubt keeps it below 81.
2 Leverage 10% Net cash ~US$80M; debt US$4.16M (leases); EBITDA negative 15 No lender, no covenants. The risk is funding, scored in #1, not leverage.
3 Dilution 10% Shares 319.9M (06-2025) → 362.2M (+13.2%), including 1.27M shares issued in lieu of cash [10]; overhang ~18.0M options/rights/RSUs (+5.0%); no ATM 70 In the +10–25% band, and another raise is likely (65%).
4 Profitability 10% FY26 net loss US$66.8M (FY25 US$35.3M); FCF about −US$63.5M on ~US$0 revenue 92 Deep losses, pre-revenue.
5 Revenue quality & concentration 10% Revenue nil for 5 years; FY26 receipts US$63k; non-equity money ~100% US government 90 "No revenue yet" band.
6 Execution & track record 10% June ~2.4 t vs 16.7 t/month target; EBITDA-2026 target dropped; furnaces late; interim-note correction (no restatement); ICFR effective 77 Frequent misses and big delays. Not a material weakness, so below 81.
7 Competitive position & disruption 10% Unproven at scale; 6K Additive at 1,000 tpa first; Chinese sponge ~US$7/kg; HAMR patents, sole US non-Kroll route 60 Contested, with a strategic niche.
8 Cyclicality & commodity/macro 10% Demand is defence-budget-driven (mild cycle); funding depends on equity-market appetite; Titan is exposed to rutile, zircon and REE prices. Peers' titanium sales fell 41–55% in 2020 [45,46], but IperionX's buyer is defence 45 Budget timing (CR) and risk appetite matter more than the economic cycle.
9 Regulatory, legal & geopolitical 5% Policy mostly a tailwind; CR new-start ban; China REE truce (Titan); no filed lawsuit; redomiciliation 48 Material but contained.
10 Valuation & expectations 10% EV US$510M on zero revenue (5× single-model FY28 revenue); ASX shorts 12.45% and rising; average target ~US$42 stale 80 Heavy and rising shorts against a fragile story.

Overall: weighted average = 0.15·76 + 0.10·15 + 0.10·70 + 0.10·92 + 0.10·90 + 0.10·77 + 0.10·60 + 0.10·45 + 0.05·48 + 0.10·80 = 11.4 + 1.5 + 7.0 + 9.2 + 9.0 + 7.7 + 6.0 + 4.5 + 2.4 + 8.0 = 66.7 ≈ 67.

Change vs last: −7 (74 → 67), almost all from the method change. The new method scores leverage separately, and IperionX's lack of debt (15) pulls the average down. The old method folded it into "financial health" (82).

Like for like, three things got worse:

  • ASX shorts went from >9% to 12.45%.
  • The founders' share pledges are now documented.
  • The stopgap budget's new-production ban.

One thing got better: the March "typo" turned out to be US$17.7M, not US$330M.

Ranking check: the risk ledger was empty before this run; it is created now with IPX as its only row. Other holdings still carry scores from the old method in research-queue.md (for example DUOT 66, REAX 63, ALM 59). IPX at 67 should sit above DUOT and REAX once they are re-scored on this method. IperionX has no revenue, while REAX is a profitable brokerage and DUOT at least has contracted revenue. It should sit below single-asset, going-concern names such as FRMI.

Calibration: pre-revenue companies with under 18 months of runway usually score 70–95. IperionX scores 67 because it has no debt, a clean audit and government co-funding. The factor table, not a default, puts it just under that range.

Conclusion

  • What you are really betting on:
    • that a batch plant making ~2–4 t a month becomes a 1,400 tpa plant within about 18 months;
    • that the Army turns prototype fasteners into serial orders at component prices;
    • that the next US$100M+ comes at least partly from Washington rather than from shareholders at US$15–20 per ADS.
  • The 2–3 things that will decide the outcome:
    1. Monthly output from July to December 2026 against 16.7 t a month.
    2. The first priced, non-prototype parts order.
    3. The source and price of the next funding.
  • Signposts:
    • Confirm the bull case:
      1. The September-quarter report shows ≥15 t for the quarter and a September exit rate ≥8 t a month.
      2. A Task Order 3 or Rheinmetall order for parts (not equipment), with a value.
      3. A government loan or equity letter for 1,400 tpa or Titan.
      4. A disclosed cost per kg near US$55, or a GenX production-line result.
    • Break the bull case:
      1. December 2026 output below ~10 t a month, or the 200 tpa target re-dated.
      2. A raise below US$15 per ADS without government co-funding.
      3. Pledged founder shares sold, or ASX shorts above 15%.
      4. FY27 defence funding stuck on a CR into 2027, with no new task orders.
  • New since the last report:
    • The March "typo" was a US$17.7M column swap with an unchanged total, not ~US$330M. ICFR is effective and the PwC audit is clean, so the credibility bear is weaker than in report #2.
    • New risks:
      • ASX shorts rose every month to 12.45% (45.1M shares).
      • Both founders have pledged shares to lenders: Hannigan added 2.55M on 2026-07-09.
      • No insider has bought since 2026-07-14.
    • The stopgap budget (signed 2026-09-02, to 2026-12-11) bans new defence production starts [39,40,41]. Tailwinds that depend on serial Army orders are pushed into 2027.

Open questions & data gaps

  • July–September output: not published. This is the single most important gap, and it decides Bear #1 and the 60% headwind. The report is due around 2026-10-29 (date unconfirmed).
  • Furnace fault and sintering furnace status: the cause is undisclosed, and whether the second large furnace is installed is not known. This matters for the December target.
  • Realised price or cost per kg, and the JLTV PO value: not disclosed ("not material"). All unit economics here rest on projections and a secondary summary of Jefferies.
  • FY28/FY29 consensus detail: paywalled, about one model. Revenue and EPS impacts are sized against thin numbers.
  • Spruce Point's PowerChem and GX Technologies related-party allegations: the company's rebuttal did not address them point by point (as far as read). This is unresolved.
  • Founder pledge balances after September: the 1.0M-share return is unconfirmed. Lenders' loan-to-value triggers are not disclosed.
  • Redomiciliation timetable, Titan FID date, integrated Atlas–Titan study date: not found.
  • Section 232 critical-minerals outcome after 2026-07-13, and the China truce extension: not confirmed by a primary source.
Sources
  1. IperionX Form 20-F, FY ended 30 June 2026 — SEC EDGAR — 2026-09-29 — https://www.sec.gov/Archives/edgar/data/1898601/000189860126000030/ipx-20260630.htm
  2. IperionX Form 20-F, FY ended 30 June 2025 — SEC EDGAR — 2025-10-14 — https://www.sec.gov/Archives/edgar/data/1898601/000189860125000013/ipx-20250630.htm
  3. IperionX September 2025 Quarterly Report (6-K Ex 99.1) — SEC EDGAR — 2025-10-30 — https://www.sec.gov/Archives/edgar/data/1898601/000114036125039862/ef20057976_ex99-1.htm
  4. IperionX December 2025 Quarterly Report — SEC EDGAR — 2026-01-30 — https://www.sec.gov/Archives/edgar/data/1898601/000114036126002866/ef20064210_ex99-1.htm
  5. IperionX March 2026 Quarterly Report — SEC EDGAR — 2026-04-27 — https://www.sec.gov/Archives/edgar/data/1898601/000114036126016841/ef20071580_ex99-1.htm
  6. IperionX June 2026 Quarterly Report incl. Appendix 5B and Figure 4 — SEC EDGAR — 2026-07-30 — https://www.sec.gov/Archives/edgar/data/1898601/000114036126030117/ef20078979_ex99-1.htm
  7. Response to ASX Price Query — SEC EDGAR — 2026-03-16 — https://www.sec.gov/Archives/edgar/data/1898601/000114036126009611/ef20068025_ex99-1.htm
  8. Correction to the 31 December 2025 Interim Financial Report (ASX notice, webull copy) — IperionX/ASX — 2026-03-13 — https://bulletin.webull.com/qbd/announcement/20260313/499500882/489ebc050266e2f9938a0308ccd28402.pdf
  9. 424B5 prospectus supplements, July 2026 ADS offering — SEC EDGAR — 2026-07-07/09 — https://www.sec.gov/Archives/edgar/data/1898601/000114036126028010/ny20077390x2_424b5.htm
  10. 424B5, 1,273,179 shares issued in lieu of cash — SEC EDGAR — 2026-02-23 — https://www.sec.gov/Archives/edgar/data/1898601/000114036126006413/ny20066270x1_424b5.htm
  11. OSW-SWIB award up to US$6.6M and JLTV purchase order — SEC EDGAR — 2026-07-01 — https://www.sec.gov/Archives/edgar/data/1898601/000114036126027050/ef20077170_ex99-1.htm
  12. IperionX Secures Second U.S. Army Task Order — SEC EDGAR — 2026-08-31 — https://www.sec.gov/Archives/edgar/data/1898601/000114036126034918/ef20081339_ex99-1.htm
  13. IperionX Validates GenX Continuous Titanium Production — SEC EDGAR — 2026-09-16 — https://www.sec.gov/Archives/edgar/data/1898601/000114036126036725/ef20082093_ex99-1.htm
  14. Proposed U.S. Redomiciliation and Board Appointment — SEC EDGAR — 2026-08-03 — https://www.sec.gov/Archives/edgar/data/1898601/000114036126030542/ef20079240_ex99-1.htm
  15. Results of General Meeting — SEC EDGAR — 2026-03-19 — https://www.sec.gov/Archives/edgar/data/1898601/000114036126010403/ef20068347_ex99-1.htm
  16. Titan Project DFS release (6-K Ex 99.1) — SEC EDGAR — 2026-06-04 — https://www.sec.gov/Archives/edgar/data/1898601/000114036126023931/ef20075531_ex99-1.htm
  17. IperionX Response to Short Seller Report — SEC EDGAR — 2025-11-17 — https://www.sec.gov/Archives/edgar/data/1898601/000114036125042388/ef20059385_ex99-1.htm
  18. IperionX Ltd. research page (report and 2025-12-01 update) — Spruce Point Capital — 2025-11-12 — https://www.sprucepointcap.com/research/iperionx-ltd
  19. Forms 3/4/4A, CIK 1898601 (29 filings 2026-03-18 to 2026-08-12) — SEC EDGAR — accessed 2026-10-11 — https://data.sec.gov/submissions/CIK0001898601.json
  20. Appendix 3Y Change of Director's Interest notices (Hannigan, Arima, Martin) — IperionX/ASX — 2026-07-10 to 2026-07-13 — https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-03110715-6A1333749
  21. Daily aggregate short position reports, IPX — ASIC — 2026-03-10 to 2026-10-05 — https://download.asic.gov.au/short-selling/short-selling-data.json
  22. Short sellers circle IperionX after typo blunder — Capital Brief — 2026-03-20 — https://www.capitalbrief.com/article/short-sellers-circle-iperionx-after-typo-blunder-as-spruce-point-hints-at-second-attack-1806f7be-b5af-475d-b035-be2d66ae74d6/
  23. IperionX shares plunge on share offering — Capital Brief — 2026-07-08 — https://www.capitalbrief.com/briefing/iperionx-shares-plunge-on-22m-share-offering-73f17e3c-338c-4853-b7f9-03b1773feee8/
  24. Jefferies initiates IperionX at Buy, US$26 (MT Newswires summary, Turkish) — Midas — 2026-09-03 — https://www.getmidas.com/midasin-kulaklari/jefferies-iperionx-icin-al-notu-ve-26-dolar-hedef-fiyatla-coverage-baslatti-p-730159
  25. IperionX Aktie: B. Riley senkt Kursziel von 52 auf 34 Dollar — boerse-global — 2026-10-03 — https://www.boerse-global.de/iperionx-aktie-b-riley-senkt-kursziel-von-52-auf-34-dollar/830421
  26. IperionX's cash pile shrinks below annual loss — ad-hoc-news — 2026-10-06 — https://www.ad-hoc-news.de/boerse/news/unternehmensnachrichten/iperionx-s-cash-pile-shrinks-below-annual-loss-as-titanium-ramp-up-stays-revenue-free/70244567
  27. IperionX Aktie: Vertrauenskrise ohne Ende — boerse-global — 2026-10-06 — https://www.boerse-global.de/iperionx-aktie-vertrauenskrise-ohne-ende/831247
  28. IPX forecast, statistics and price history — stockanalysis.com (S&P Global data) — accessed 2026-10-11 — https://stockanalysis.com/stocks/ipx/forecast/
  29. IPX analyst ratings and short interest — MarketBeat — accessed 2026-10-11 — https://www.marketbeat.com/stocks/NASDAQ/IPX/short-interest/
  30. Mineral Commodity Summaries 2026: Titanium and Titanium Dioxide — USGS — 2026-02 — https://pubs.usgs.gov/periodicals/mcs2026/mcs2026-titanium.pdf
  31. Quarterly Review to 30 June 2026 — Iluka Resources (ASX) — 2026-07-28 — https://announcements.asx.com.au/asxpdf/20260728/pdf/0723lrry1qs81t.pdf
  32. 6K Additive expansion to deliver five-fold increase in powder — Metal AM — 2026 — https://www.metal-am.com/6k-additive-expansion-to-deliver-five-fold-increase-in-powder/ (search summary only)
  33. 6K Additive Q2 2026 earnings summary — Quartr — 2026-07-30 — https://quartr.com/events/6k-additive-inc-6ka-q2-2026_F1EvT8HL (secondary)
  34. Titanium dioxide steady, titanium sponge mildly higher on cost — Shanghai Metals Market — 2026-05-28 — https://news.metal.com/en/newscontent/103926923-smm-analysis-titanium-dioxide-steady-titanium-sponge-mildly-higher-on-cost
  35. Dysprosium oxide Europe vs China (Fastmarkets quote) — MINING.COM on X — 2026-09-10 — https://x.com/mining/status/2098067340323627386 (secondary)
  36. Heavy rare earth prices: dysprosium, terbium ex-China — Rare Earth Exchanges — 2026-10-02 — https://rareearthexchanges.com/news/heavy-rare-earth-prices-dysprosium-terbium-ex-china/ (paywalled preview)
  37. Adjusting Imports of Processed Critical Minerals and Their Derivative Products — The White House — 2026-01-14 — https://www.whitehouse.gov/presidential-actions/2026/01/adjusting-imports-of-processed-critical-minerals-and-their-derivative-products-into-the-united-states/
  38. Results of critical minerals investigation under Section 232 — Covington & Burling — 2026-01 — https://www.cov.com/news-and-insights/insights/2026/01/trump-administration-announces-results-of-critical-minerals-investigation-under-section-232-and-directs-us-officials-to-initiate-negotiations
  39. Congressional Bill H.R. 6500 Signed into Law — The White House — 2026-09-02 — https://www.whitehouse.gov/briefings-statements/2026/09/congressional-bill-h-r-6500/
  40. New CR blocks new defense production starts — GovConWire — 2026-09 — https://www.govconwire.com/articles/continuing-resolution-fy2027-funding-signed
  41. Continuing Appropriations and Extensions Act, 2027 (R49353) — Congressional Research Service — 2026-09-17 — https://www.everycrsreport.com/files/2026-09-17_R49353_23c606391f06ea931ebe02a8ffd1e374d807cca9.pdf
  42. Department of War's Office of Strategic Capital posts offering — Baker Botts — 2026-08-27 — https://www.bakerbotts.com/thought-leadership/publications/2026/august/department-of-wars-office-of-strategic-capital-posts-offering
  43. China rare earth export pause nears expiry — Mining Technology — 2026 — https://www.mining-technology.com/news/china-rare-earth-export-pause-nears-expiry-amid-persistent-supply-concentration/
  44. Chinese rare earth exports: Trump–Xi truce extended — Rinnovabili — 2026-09-25 — https://www.rinnovabili.net/policy-and-affairs/environmental-policies/chinese-rare-earth-exports-trump-xi-truce/ (single source, UNCONFIRMED)
  45. ATI Announces Fourth Quarter 2020 Results — ATI — 2021-01 — https://s27.q4cdn.com/226628310/files/doc_news/2021/01/ATI-Announces-Fourth-Quarter-2020-Results.pdf
  46. Financial Results FY ended 31 March 2022 — Osaka Titanium Technologies — 2022-05 — http://www.osaka-ti.co.jp/e/e_ir/pdf/e-kessan202203.pdf
  47. IperionX Limited investigation page — Glancy Prongay Wolke & Rotter — 2026-03 — https://www.glancylaw.com/cases/iperionx-limited/
  48. IPX Company Presentation — IperionX — 2026-07-03 — https://iperionx.com/wp-content/uploads/2026/07/2026.07.03-IPX-Company-Presentation.pdf
  49. Trilogy Metals announces definitive agreements for strategic equity investment by the U.S. Department of War — Trilogy Metals — 2026-08-28 — https://www.placera.se/pressmeddelanden/trilogy-metals-announces-execution-of-definitive-agreements-for-strategic-equity-investment-by-the-u-s-department-of-war-20260828
  50. Pentagon taking big stake in rare earth company (MP Materials) — Bloomberg via Yahoo Finance — 2025-07 — https://finance.yahoo.com/news/pentagon-taking-big-stake-rare-221823226.html
  51. ATI Q2 2026 Form 10-Q — ATI / SEC EDGAR — 2026-08-05 — https://www.sec.gov/Archives/edgar/data/0001018963/000162828026054233/ati-20260628.htm (search summary only)
All IPX Bulls vs Bears reports
Disclaimer. AI-generated research and podcast (Claude by Anthropic, voices by Google Gemini) for educational purposes — not financial advice and not a recommendation to buy or sell. Willem (MR.INVEST) owns this stock. Check the company’s own filings before making any decision.
← All Bulls vs Bears reports